Rationales for discontinuation of disease-modifying antirheumatic drugs, biologic agents, and tofacitinib in rheumatoid arthritis

Objective: to analyze the reasons for discontinuation of traditional disease-modifying antirheumatic drugs (tDMARDs), biologic agents (BAs), and tofacitinib (TOFA) in patients with rheumatoid arthritis (RA) in real clinical practice.Patients and methods. The authors carried out a retrospective analy...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Yu. V. Muraviev, G. I. Gridneva, L. A. Muravieva, N. V. Muravieva, A. V. Alexeeva, K. S. Nurbaeva, K. M. Mikhailov, A. V. Rozov
Médium: Artigo
Jazyk:Russo
Vydáno: IMA-PRESS LLC 2018-12-01
Edice:Современная ревматология
Témata:
rheumatoid arthritis
disease-modifying antirheumatic drugs
biologic agents
adverse reactions
treatment inefficiency
On-line přístup:https://mrj.ima-press.net/mrj/article/view/869
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky